Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

[1]  V. Giudicelli,et al.  IMGT(R), the international ImMunoGeneTics information system(R). , 2022 .

[2]  S. Rowland-Jones,et al.  Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.

[3]  Qiang Zhou,et al.  A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 , 2020, Science.

[4]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[5]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[6]  A. Sette,et al.  The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients , 2020, Science Immunology.

[7]  L. Stamatatos,et al.  Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation , 2020, Immunity.

[8]  M. Nussenzweig,et al.  Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies , 2020, bioRxiv.

[9]  Linqi Zhang,et al.  Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.

[10]  Amalio Telenti,et al.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.

[11]  X. Xie,et al.  Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.

[12]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals , 2020, bioRxiv.

[13]  Larissa B. Thackray,et al.  Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein , 2020, bioRxiv.

[14]  L. Stamatatos,et al.  Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual , 2020, bioRxiv.

[15]  M. V. van Breemen,et al.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[16]  D. Burton,et al.  Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model , 2020, bioRxiv.

[17]  A. Sette,et al.  The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus Antibodies , 2020, medRxiv.

[18]  Qiang Zhou,et al.  A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability , 2020, bioRxiv.

[19]  F. Gao,et al.  A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 , 2020, Science.

[20]  D. Montefiori,et al.  Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2 , 2020, bioRxiv.

[21]  J. Bloom,et al.  Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays , 2020, bioRxiv.

[22]  Wenhui Li,et al.  The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement , 2020, bioRxiv.

[23]  J. Zhao,et al.  Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor , 2020, Cellular & Molecular Immunology.

[24]  Baoying Huang,et al.  Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells , 2020, bioRxiv.

[25]  Amalio Telenti,et al.  Structural and functional analysis of a potent sarbecovirus neutralizing antibody , 2020, bioRxiv.

[26]  C. Chiang.  Faculty Opinions recommendation of SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[27]  Y. Wen,et al.  Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.

[28]  I. Wilson,et al.  A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.

[29]  Yan Liu,et al.  Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.

[30]  Lei Liu,et al.  Potent human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, bioRxiv.

[31]  K. Shi,et al.  Structural basis of receptor recognition by SARS-CoV-2 , 2020, Nature.

[32]  Qi Zhao,et al.  Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 , 2020, International journal of biological sciences.

[33]  Nicholas C. Wu,et al.  A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.

[34]  Frank Grosveld,et al.  A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.

[35]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[36]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[37]  Young-Jun Park,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[38]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[39]  A. Ward,et al.  Structure and immune recognition of the porcine epidemic diarrhea virus spike protein , 2020, bioRxiv.

[40]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[41]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[42]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[43]  J. Nie,et al.  Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2 , 2020, Emerging microbes & infections.

[44]  D. Burton,et al.  Mapping polyclonal antibody responses in non-human primates vaccinated with HIV Env trimer subunit vaccines , 2019, bioRxiv.

[45]  John L Rubinstein,et al.  The human coronavirus HCoV-229E S-protein structure and receptor binding , 2019, eLife.

[46]  J. McLellan,et al.  The 3.1-Angstrom Cryo-electron Microscopy Structure of the Porcine Epidemic Diarrhea Virus Spike Protein in the Prefusion Conformation , 2019, Journal of Virology.

[47]  T. Fung,et al.  Human Coronavirus: Host-Pathogen Interaction. , 2019, Annual review of microbiology.

[48]  D. Veesler,et al.  Structural insights into coronavirus entry , 2019, Advances in Virus Research.

[49]  Alexandra C Walls,et al.  Structural basis for human coronavirus attachment to sialic acid receptors , 2019, Nature Structural & Molecular Biology.

[50]  J. Mascola,et al.  Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope , 2019, Immunity.

[51]  A. Walls,et al.  Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion , 2019, Cell.

[52]  F. Grosveld,et al.  Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein , 2019, Emerging microbes & infections.

[53]  D. Burton,et al.  Commonality despite exceptional diversity in the baseline human antibody repertoire , 2018, Nature.

[54]  Daniel Wrapp,et al.  Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis , 2018, Scientific Reports.

[55]  D. Burton,et al.  Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization , 2018, Immunity.

[56]  Thomas C Terwilliger,et al.  A fully automatic method yielding initial models from high-resolution electron cryo-microscopy maps , 2018, Nature Methods.

[57]  Trevor Bedford,et al.  Nextstrain: real-time tracking of pathogen evolution , 2017, bioRxiv.

[58]  A. Walls,et al.  Glycan Shield and Fusion Activation of a Deltacoronavirus Spike Glycoprotein Fine-Tuned for Enteric Infections , 2017, Journal of Virology.

[59]  Fang Li,et al.  Cryo-Electron Microscopy Structure of Porcine Deltacoronavirus Spike Protein in the Prefusion State , 2017, Journal of Virology.

[60]  A. Walls,et al.  Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion , 2017, Proceedings of the National Academy of Sciences.

[61]  Barney S. Graham,et al.  Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen , 2017, Proceedings of the National Academy of Sciences.

[62]  Yi Shi,et al.  Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains , 2017, Nature Communications.

[63]  Yuelong Shu,et al.  GISAID: Global initiative on sharing all influenza data – from vision to reality , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[64]  David J. Fleet,et al.  cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination , 2017, Nature Methods.

[65]  Stefan Elbe,et al.  Data, disease and diplomacy: GISAID's innovative contribution to global health , 2017, Global challenges.

[66]  Haixia Zhou,et al.  Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding , 2016, Cell Research.

[67]  C. Rice,et al.  Supplemental Information Identification of Interferon-stimulated Genes with Antiretroviral Activity , 2022 .

[68]  M. Nussenzweig,et al.  Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site , 2016, Nature Structural &Molecular Biology.

[69]  D. Falzarano,et al.  SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.

[70]  Muyuan Chen,et al.  High resolution single particle refinement in EMAN2.1. , 2016, Methods.

[71]  Barney S. Graham,et al.  Pre-fusion structure of a human coronavirus spike protein , 2016, Nature.

[72]  F. Dimaio,et al.  Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer , 2016, Nature.

[73]  N. Grigorieff,et al.  CTFFIND4: Fast and accurate defocus estimation from electron micrographs , 2015, bioRxiv.

[74]  A. McDowall,et al.  Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env , 2015, Cell.

[75]  Ulas Bagci,et al.  Evaluation of candidate vaccine approaches for MERS-CoV , 2015, Nature Communications.

[76]  Lisa E. Gralinski,et al.  Molecular pathology of emerging coronavirus infections , 2014, The Journal of pathology.

[77]  Patrice Duroux,et al.  IMGT®, the international ImMunoGeneTics information system® 25 years on , 2014, Nucleic Acids Res..

[78]  Jiye Shi,et al.  SAbDab: the structural antibody database , 2013, Nucleic Acids Res..

[79]  Ralph S. Baric,et al.  A decade after SARS: strategies for controlling emerging coronaviruses , 2013, Nature Reviews Microbiology.

[80]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[81]  K. Katoh,et al.  MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.

[82]  L. Enjuanes,et al.  Structural Bases of Coronavirus Attachment to Host Aminopeptidase N and Its Inhibition by Neutralizing Antibodies , 2012, PLoS pathogens.

[83]  D. Higgins,et al.  Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega , 2011, Molecular systems biology.

[84]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[85]  I. Wilson,et al.  A structural analysis of M protein in coronavirus assembly and morphology , 2010, Journal of Structural Biology.

[86]  S. Plotkin.  Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.

[87]  Pamela J. Bjorkman,et al.  Few and Far Between: How HIV May Be Evading Antibody Avidity , 2010, PLoS pathogens.

[88]  O. Gascuel,et al.  New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. , 2010, Systematic biology.

[89]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[90]  Paramvir S. Dehal,et al.  FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments , 2010, PloS one.

[91]  W. Kabsch.  XDS , 2010, Acta crystallographica. Section D, Biological crystallography.

[92]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[93]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[94]  S. Plotkin,et al.  Vaccines: correlates of vaccine-induced immunity. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[95]  R. Baric,et al.  Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge , 2008, Journal of Virology.

[96]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[97]  Conrad C. Huang,et al.  Visualizing density maps with UCSF Chimera. , 2007, Journal of structural biology.

[98]  William C. Hwang,et al.  Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80R* , 2006, Journal of Biological Chemistry.

[99]  Yang Feng,et al.  Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody* , 2006, Journal of Biological Chemistry.

[100]  David N Mastronarde,et al.  Automated electron microscope tomography using robust prediction of specimen movements. , 2005, Journal of structural biology.

[101]  Ying Tang,et al.  Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. , 2005, Journal of molecular biology.

[102]  Itay Mayrose,et al.  ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures , 2005, Nucleic Acids Res..

[103]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[104]  Sara Sandin,et al.  Structure and flexibility of individual immunoglobulin G molecules in solution. , 2004, Structure.

[105]  Garrett M. Morris,et al.  Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design , 2001, Science.

[106]  S. Plotkin.  Immunologic correlates of protection induced by vaccination , 2001, The Pediatric infectious disease journal.

[107]  L J Harris,et al.  Crystallographic structure of an intact IgG1 monoclonal antibody. , 1998, Journal of molecular biology.

[108]  G. Nolan,et al.  Production of high-titer helper-free retroviruses by transient transfection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[109]  Alexander McPherson,et al.  The three-dimensional structure of an intact monoclonal antibody for canine lymphoma , 1992, Nature.